Description
P-21 is a synthetic neurotrophic peptide developed by Dr. Khalid Iqbal’s research team. Its core sequence — DGGL — corresponds to residues 147–150 of ciliary neurotrophic factor (CNTF). An adamantane moiety is attached to this tetrapeptide core. This modification increases lipid solubility and metabolic stability, enabling blood-brain barrier penetration that the bare CNTF-derived sequence lacks. P-21 is studied in nootropic peptide CNS research models for its effects on BDNF expression, dentate gyrus neurogenesis, and LIF/STAT3 pathway inhibition. Its mechanism was characterized in foundational preclinical work published by Li et al. in FEBS Letters (2010).
Key Characteristics
- LIF/STAT3 pathway inhibition is the initiating step in P-21’s mechanistic cascade — leukemia inhibitory factor (LIF) signaling suppresses neurogenesis; by inhibiting this pathway, P-21 removes an inhibitory brake rather than simply adding a stimulatory signal, which distinguishes its approach from direct neurotrophic factor supplementation
- BDNF upregulation follows LIF inhibition downstream — increased BDNF activates TrkB/CREB signaling, reduces GSK-3β activity, and drives dentate gyrus neurogenesis and synaptic marker restoration; the BDNF-mediated outcome is shared with Semax research, but the upstream mechanism is different — P-21 disinhibits the neurogenic environment while Semax acts through ACTH-derived melanocortin receptor interaction
- The adamantane moiety is structurally critical — it provides BBB penetration and enzymatic resistance that the bare DGGL tetrapeptide lacks; the modification is a rational design choice, not an incidental addition, and is what makes CNS-relevant concentrations achievable in preclinical models
- Synaptic marker restoration — specifically PSD-95, MAP2, and glutamate receptor expression — has been documented in preclinical aging and neurodegeneration models alongside BDNF effects; this synaptic dimension extends P-21’s research relevance beyond neurogenesis into synaptic plasticity biology
- All evidence is preclinical; no human clinical trials have been conducted; the evidence base derives primarily from the Iqbal laboratory and affiliated groups
Handling and Storage
Store as lyophilized powder under refrigeration, away from heat, moisture, and light. The adamantane modification improves metabolic stability relative to unmodified tetrapeptides. Reconstitute immediately before use and avoid repeated freeze-thaw cycles.
FAQs
What is P-21?
P-21 is a synthetic tetrapeptide derived from residues 147–150 of ciliary neurotrophic factor (CNTF). It is modified with an adamantane moiety for blood-brain barrier penetration and metabolic stability. It is studied for LIF/STAT3 pathway inhibition, BDNF upregulation, dentate gyrus neurogenesis, and synaptic marker restoration in preclinical CNS models. All evidence is preclinical.
How does P-21’s mechanism differ from Semax in BDNF research?
Both compounds produce BDNF upregulation as a downstream outcome in CNS research models. The upstream routes are different. Semax acts through ACTH-derived melanocortin receptor interaction to modulate TrkB pathway activity. P-21 first inhibits LIF/STAT3 signaling — removing an inhibitory constraint on neurogenesis — then drives BDNF expression as a downstream consequence. Researchers select between them based on whether the study requires receptor-mediated neurotrophic modulation or disinhibition-driven neurogenic environment research.
Why is the adamantane modification significant for P-21 research design?
The bare DGGL tetrapeptide core lacks sufficient lipid solubility and metabolic stability to reach CNS tissue at meaningful concentrations. The adamantane moiety solves both problems simultaneously — it increases membrane permeability for BBB crossing and provides resistance to enzymatic degradation in plasma. Without this modification, P-21’s preclinical CNS findings would not be reproducible. Researchers should note that the adamantane component also affects the compound’s molecular weight and analytical detection profile relative to unmodified tetrapeptides.
